-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Morgan Stanley Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Overweight Rating

Morgan Stanley Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Overweight Rating

MT Newswires · 01/06/2023 05:55